Figure 3
EAE-induced neuropathic pain-like behaviors persist for 6 weeks in female C57BL/6 mice. Administration of MOG35-55 increased neurological motor deficits (A) and decreased forelimb grip strength (B), but did not change weight gain (C) relative to CFA controls. Female mice that received MOG35-55 displayed decreased mechanical withdrawal thresholds (D) and increased duration of response to acetone stimulation (E) when compared to CFA-treated controls. Response to heat stimulation did not differ between mice that received MOG35-55 or CFA alone (F). MOG35-55 injections began on day 0. BL baseline. Values represent mean ± SEM. ★P < 0.05 compared to sex- and age-matched CFA control (one-way ANOVA). N = 8–18/group.